OLEMA PHARMACEUTICALS INC. - COMMON STOCK

Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025

25 Apr 2025 13:00:00 By Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Apr 2025 16:30:00 By Nasdaq GlobeNewswire

Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting

25 Mar 2025 16:31:00 By Nasdaq GlobeNewswire

Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

18 Mar 2025 16:01:00 By Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Mar 2025 16:30:00 By Nasdaq GlobeNewswire

Olema Oncology to Present at the TD Cowen 45th Annual Health Care Conference

19 Feb 2025 16:30:00 By Nasdaq GlobeNewswire

Olema Oncology Appoints Shawnte M. Mitchell, J.D. as Chief Legal Officer and Corporate Secretary

18 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Feb 2025 16:30:00 By Nasdaq GlobeNewswire

Olema Oncology to Participate in Upcoming Investor Conferences

03 Feb 2025 16:30:00 By Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Jan 2025 16:30:00 By Nasdaq GlobeNewswire

Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference

02 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium

10 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor

09 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Dec 2024 16:30:00 By Nasdaq GlobeNewswire

Olema Oncology Announces New Clinical Trial Collaboration and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private Placement

02 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium

25 Nov 2024 17:30:00 By Nasdaq GlobeNewswire

Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

12 Nov 2024 16:01:00 By Nasdaq GlobeNewswire

Olema Oncology to Participate in Upcoming Investor Conferences

06 Nov 2024 07:01:11 By Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Nov 2024 16:44:36 By Nasdaq GlobeNewswire

Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024

23 Oct 2024 07:00:00 By Nasdaq GlobeNewswire